ALFA News
Straight from the exchange filing
Every announcement Sudarshan Pharma Industries has filed with the exchanges that we have reported, newest first. Each story links the original filing.
Every Sudarshan Pharma Industries announcement on ALFA FilingsSee filings →Reference market data from a third-party provider, as of the most recent story. Not a valuation or a recommendation.
Sudarshan Pharma Industries board approves issuing 72 crore convertible warrants to promoters. Read about the company's growth plans and latest Q2 FY27 results.
Sudarshan Pharma Industries reports a 92.9% YoY jump in net profit to ₹8.1 crore for Q2 FY27, with revenue growing 28% to ₹217 crore and improved margins.
Sudarshan Pharma Industries schedules board meeting for Oct 29, 2026, to approve Q2 FY27 results and a fresh fund-raising proposal via equity or debt instruments.
Sudarshan Pharma Industries migrates from BSE SME to NSE Main Board on October 27, 2026. Company reports 35.5% YoY profit growth and ₹752.06 Cr market cap.
Sudarshan Pharma Industries allots $10 million in 8% senior unsecured FCCBs due 2029 at a conversion price of ₹30.19 per share to strengthen capital reserves.
